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Abstract
Background: The PathOlogist is a new tool designed to transform large sets of gene expression data into
quantitative descriptors of pathway-level behavior. The tool aims to provide a robust alternative to the search for
single-gene-to-phenotype associations by accounting for the complexity of molecular interactions.
Results: Molecular abundance data is used to calculate two metrics - ‘activity’ and ‘consistency’ - for each pathway
in a set of more than 500 canonical molecular pathways (source: Pathway Interaction Database, http://pid.nci.nih.
gov). The tool then allows a detailed exploration of these metrics through integrated visualization of pathway
components and structure, hierarchical clustering of pathways and samples, and statistical analyses designed to
detect associations between pathway behavior and clinical features.
Conclusions: The PathOlogist provides a straightforward means to identify the functional processes, rather than
individual molecules, that are altered in disease. The statistical power and biologic significance of this approach are
made easily accessible to laboratory researchers and informatics analysts alike. Here we show as an example, how
the PathOlogist can be used to establish pathway signatures that robustly differentiate breast cancer cell lines
based on response to treatment.
Background
Recent biomedical research has made great strides in
unveiling the complexity of human disease. Technological
breakthroughs and innovative methodologies now allow a
much more detailed account of molecular behavior. Fre-
quently however, such studies yield a plethora of data,
with results too complex for traditional analyses designed
to identify single genes associated with disease.
Accordingly, many researchers are employing new fra-
meworks to understand disease. One such framework is
the concept of pathways - sets of molecular interactions
that progress towards a given function. Analysis at the
pathway level accounts for some of the data complexity
by integrating information from across the entire genome
while mirroring real biological processes. Central to path-
way analysis is the idea that disruption of the benign
behavior of a pathway as a whole, not necessarily a single
gene component of the pathway, could be the basis for
disease.
The potential benefits of molecular analysis at the path-
way level have gained increasing recognition recently,
and consequently a number of tools have been developed
to visualize pathway structures (Cytoscape [1], Ariadne
Pathway Studio [2], PathVisio [3]) and predict novel
pathways from experimental data (SRI Pathway Tools [4],
GenePath [5]). However, tools to facilitate quantitative
informatics-level analyses of established pathways are
much less prevalent. To fully explore this promising
mode of investigation, a resource is needed that provides
a robust and straightforward means to transform large-
scale molecular data into meaningful metrics that
account for gene relationships at the pathway level.
The PathOlogist is designed to automatically analyze
genetic data within the context of molecular pathways.
The tool aims to facilitate both a quantitative and quali-
tative analysis of pathway behavior in a format accessible
to both laboratory researchers and informatics analysts.
The PathOlogist uses RNA expression data to calculate
2 descriptive metrics - ‘activity’ and ‘consistency’ (see
Efroni et al. [6] for motivation and more detailed explana-
tion) - for each pathway in a set of more than 500 canoni-
cal pathways (source: Pathway Interaction Database [7])
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shown to be more efficient than individual gene expres-
sion at distinguishing samples of different tumor grades
and predicting disease outcome in cancer samples [6]. The
metrics make use of the structure of gene relationships
within in the pathway, rather than treating the genes as
simply a uniform set of entities. A pathway is defined as a
network of molecular interactions; each interaction con-
sists of one or more input genes, promoters and inhibitors,
and one or more output genes. An activity score and a
consistency score is calculated for each interaction based
on the expression of all input and output genes. Activity
scores provide a measure of how likely the interactions are
to occur while consistency scores determine whether these
interactions follow the logic of the defined network struc-
ture. Depending on the nature of the samples, these scores
can reveal various types of information. For example, one
may compare activity scores calculated from expression
data collected at different timepoints to identify functional
processes that have been activated or de-activated over
time. Comparing consistency scores calculated from sets
of tumor and matched normal samples can reveal path-
ways whose ordinary behavior has been altered by disease.
The PathOlogist facilitates such analyses through a num-
ber of features. A clustered heatmap of pathway scores can
be generated to provide an overview of the metrics and
quickly identify any inherent groupings of samples or sets
of pathways that act in concert. The network structure of a
pathway and metrics for individual interactions can be
viewed as a color-coded graphic, which proves useful for
direct comparison of samples and identification of specific
areas within the pathway that deviate from normal beha-
vior. Finally, the tool provides an interface for conducting a
number of statistical tests to detect associations between
pathway scores and additional sample information (for
example, disease grade or response to treatment).
Implementation
The PathOlogist is a MATLAB-based application, which
can be run as a GUI in the MATLAB environment or as a
standalone executable (with slightly more limited function-
ality). The objective of the PathOlogist is to transform stan-
dard gene or molecule-based data into meaningful,
quantifiable information at the pathway level. Our method
accomplishes this efficiently using a short sequence of ana-
lytic steps designed to maximize fidelity to the original data
as well as comparability across studies. The PathOlogist
then provides for in-depth analysis of the calculated metrics,
through data visualization and statistical tests of association.
Input
The PathOlogist is designed to analyze normalized abun-
d a n c ed a t af r o ma n yg e n e - b a s e dm i c r o a r r a yp l a t f o r m ,h o w -
ever special features are included to accept Affymetrix data
in its raw state as well. The user may upload a set of .cel
files reporting probe-level hybridization readings in an
arrangement specific to the microarray chip used in the
experiment. These .cel files as well as a chip-specific map-
ping file (easily obtainable from the microarray’s commer-
cial website), are the sole input to the PathOlogist
necessary to carry out the process of pathway analysis.
Once loaded, raw data can be summarized into probesets
and normalized using the robust-multichip averaging
(RMA) method developed by Irizarry et al [8]. This method
is widely used and has been validated as an effective
approach in a number of studies [9]. (Note that the RMA-
normalization feature is not available in the standalone
version.)
Data can also be summarized before input to the tool
using RMAexpress http://rmaexpress.bmbolstad.com/).
If raw files are not available or if other platforms were
used, normalized probeset-based abundance data can be
loaded in the form of a textfile.
Up-Down Normalization
Once the data is defined at the probeset level, a unique
algorithm is applied which calculates the probability that
each sample is in an ‘up’ (highly expressive) or ‘down’
(minimally expressive) state, by fitting the set of intensity
readings for a probeset to a mixture of two gamma distri-
butions [6]. The value of this technique is two-fold. First,
it effectively places all expression values on a unit scale,
allowing direct comparison between different probes, sam-
ples, and experiments. This is important for down-stream
analysis in which the expression of multiple interacting
genes is evaluated in combination. Additionally, this extra
normalization tends to significantly reduce noise in highly
variable intensity readings, while retaining much more
information than a simple ‘presence/absence’ call.
Pathway Metrics Calculations
The PathOlogist uses normalized expression data to cal-
culate two descriptive metrics for each pathway selected.
For this purpose, a pathway is defined as a connected
set of interactions, each consisting of one or more input
molecules and one or more output molecules.
Source of pathway data
Currently, the PathOlogist uses the PID (Pathway Inter-
action Database) [7] as the source of pathway structure
data. This database is a collection of over 500 canonical
pathways, including pathways curated by Nature Publish-
ing Group editors and pathways imported from BioCarta
and Kegg. The network structure for each pathway is
contained within the tool, and can be updated as new
pathways are added to the database.
Mapping probes to genes
Mapping probe-level intensity values to molecules within
a pathway is accomplished using a platform-specific text
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This data is contained within the tool for a number of
commonly used platforms. An option also exists allowing
the addition of new user-created mapping files, extending
the tool’s capabilities to virtually any platform.
Calculations
Users can select any subset of samples and pathways to
include in metrics calculations. ‘Activity’ and ‘consistency’
metrics are calculated for each pathway selected, based on
the normalized expression of input and output elements
for each sample. Calculations are first performed at the
interaction level and then averaged over all the interac-
tions in a pathway to generate a final pathway score. For
each interaction, the metrics are calculated as defined in
Figure 1, where p(A) indicates the probability of gene A
being in the ‘up’ (highly expressive) state. Note that for
inhibitory molecules, 1-p(A) is used instead.
Essentially, activity is a measurement of an interac-
tion’s potential to occur, as determined by the expres-
sion of input molecules. An activity score of ‘1’ for an
interaction indicates that all positively regulating ele-
ments are being highly expressed, while inhibitory ele-
ments are unexpressed. Consistency scores compare this
potential with the actual presence of output molecules,
providing an account of deviations from expected path-
way logic. Since these two metrics are averaged over all
the interactions within a pathway to generate scores for
the pathway as a whole, alterations anywhere within the
pathway will have the same overall effect.
At the end of the process, each sample will have two
scores describing the behavior of each pathway. These
scores can then replace individual gene expression
values in any desired informatics or statistical analysis.
Metrics Visualizations
After pathway metrics have been calculated, the PathOl-
ogist facilitates a detailed investigation of the results.
Heatmap
A heatmap feature displays activity and/or consistency
scores as a bi-dimensionally clustered heatmap. This can
be used as a summary view, to quickly identify subgroups
within the data. Specific subsets of pathways and samples
can be selected for a more directed view as well.
Network Graphic
For a specific pathway of interest, a pathway-drawing fea-
ture generates a directed network graphic for each of the
samples selected, detailing the structure and behavior of
the pathway. In the graphic, metrics for individual inter-
actions are displayed visually using node color and size. If
desired, the drawing may overlay gene-specific data such
as copy number alterations or methylation status. An
option also exists to extend the network to include all
interactions from other pathways that involve genes
within the pathway of interest. Graphics for multiple
samples can be compared to iden t i f ys p e c i f i cp o i n t so f
differentiation within the pathway. Clicking on any gene
within the pathway will link to more detailed informa-
tion, courtesy of the CGAP Gene database [10]. The net-
work structure and individual interaction metrics can
also be generated in text format. (Graphic format not
available in standalone version).
Identifying Important Pathways
The PathOlogist performs statistical analyses to deter-
mine the relationship between pathway behavior and
sample features such as class, survival, etc. Sample data
is entered through a simple copy-paste procedure or by
uploading a two-column text file. Four types of analysis
are possible:
Binary classification
finds pathways whose scores can be used to differentiate
two classes of samples (eg. cancer v. normal). For each
pathway, a two-sample ranksum test is performed to eval-
uate the null hypothesis that pathway scores of class A
and class B are samples from normal distributions with
equal means and variances. Significant pathways are those
for which the null hypothesis is highly unlikely, indicating
that the pathway behaves differently in these two groups
of samples.
Linear correlation
finds pathways whose scores correlate well with a con-
tinuous variable (eg. response to treatment, measured as
concentration of drug required to initiate cell death).
For each pathway, the Pearson’s correlation coefficient is
calculated for the linear relationship between the set of
pathway scores and the set of sample data. A p-value is
then calculated for each pathway, using a Student’st
distribution to evaluate the null hypothesis that the cor-
relation coefficient is zero. Significant pathways are
those which show either highly positive or highly nega-
tive correlation with the associated variable.
Survival
finds pathways that influence sample survival. The set of
scores for each pathway are partitioned into two groups
using kmeans clustering to minimize the squared
Activity =p(A)*p(B)
Consistency =[Activity*p(C)]
+[(1ͲActivity)*(1Ͳ p(C))]
geneC
geneA geneB
interaction
Figure 1 Activity and consistency scores are calculated for
each interaction within a pathway.
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mum group size can be set by the user.) Cumulative
survival distributions are calculated separately for these
two groups of samples using the Kaplan-Meier algo-
rithm, and a logrank test is performed to evaluate the
null hypothesis that the two sample groups are drawn
from the same population. Significant pathways are
those for which pathway behavior can be used as a mar-
ker dividing samples into groups with highly differen-
tiated survival curves.
Gene hits targeting
f i n d sp a t h w a y sw h o s em o l e c u l e sa r et h et a r g e to fs o m e
alteration (eg. copy number, mutations). Gene-specific
alterations are uploaded as a matrix of logical values
describing which of the assayed genes were altered in
each sample. For each pathway, a hypergeometric cumu-
lative distribution function is computed for each sample
to estimate the probability that genes within the path-
way are altered more often than would be expected,
given the overall distribution of gene alterations for that
sample. An overall p-value for the pathway is calculated
by applying a Fisher’s Omnibus test to the set of prob-
abilities across all samples. Pathways with a significant
p-value are those which comprise a set of genes that are
disproportionately altered in multiple samples (although
the specific genes altered are not necessarily the same in
different samples).
Each test can be performed on all samples or specific
classes of samples, and returns a list of all pathways
ordered by significance, along with corresponding p-
values. These results can be plotted for visual confirma-
tion of association, and then written to text files.
Results
The power of pathway-level molecular analysis, and the
value of the PathOlogist in facilitating such analysis, has
been explored using a number of datasets with various
features; the results of two such analyses are reported
here, using 1) expression and copy number data from a
set of 28 cancer cell lines treated with an anti-cancer
drug, and 2) expression and survival data obtained from
377 glioblastoma multiforme (GBM) tumor samples,
and 10 unmatched normal samples from the publicly
accessible TCGA database.
Pathway Behavior and Drug Sensitivity in Cancer Cell
Lines
A recently-analyzed data set assessed the expression
profile and drug sensitivity of 28 cell lines maintained
by the NCI60 Human Tumor Cell Line Screen [11] as
part of NCI’s Developmental Therapeutics program.
These cell lines were derived from tumors with a variety
of cancers and genotypic subtypes. After measuring
basal gene expression, each of the cell lines was treated
with an anti-cancer drug, and the GI50 concentration
(the concentration of drug that causes 50% growth inhi-
bition) was recorded for each. The goal was to identify
molecular signatures in the cell lines that would help
predict a patient’s response to treatment. Additionally,
copy number data and other clinical information was
available for each cell line.
The set of .cel files for the 28 lines were loaded into
the PathOlogist for RMA normalization. Up-Down
Probability normalization was then applied to the RMA
data, and the results were used to calculate activity and
consistency scores for each pathway in the database. A
bi-dimensionally-clustered heatmap of the scores is
shown in Figure 2a.
From the heatmap, it appears that the samples do not
cluster naturally into separate groups when taking all
pathway scores into account. Further analysis is needed
to identify specific pathways that influence response to
treatment. Thus, GI50 scores (entered as -log[GI50],
where GI50 is the drug concentration in moles/liter) for
each of the cell lines were loaded into the PathOlogist,
and a Pearson linear correlation coefficient was calcu-
lated for the set of activity or consistency scores asso-
ciated with each pathway. An ordered list of pathways
and Bonferroni-corrected p-values is shown in Table 1.
From this list we can see that a small set of pathways
(n = 7) are significantly correlated with drug sensitivity
at the 0.05 level. By contrast, when we shuffled the sam-
ple labels and re-performed the correlation analysis 10
times, none of these shuffled distributions produced a
single significant correlation after Bonferroni adjust-
ment. Additionally, the PathOlogist was used to depict
these relationships in scatterplot form for a few of the
top pathways in order to visually confirm the correlation
(Figure 3).
When these pathways are used in a heatmap (as in
Figure 4), most of the samples cluster into tight groups
based on sensitivity. After correcting for multiple com-
parison testing (using a Bonferroni adjustment), the
most significant pathways are more highly correlated to
GI50 than any one probeset.
In addition to identifying pathways whose behavior is
differentially altered, it may be useful to gain more
i n s i g h ti n t ow h a td r i v e st h e se alterations. In order to
explore this further, copy number data for each of the
cell lines was loaded into the tool, and the PathOlogist
was used to find pathways whose components were
altered by copy number changes.
We find that one of these pathways, the ‘Toll-like
receptor signaling pathway’ was also one of the path-
ways most predictive of drug response. We therefore
assessed whether copy number alterations in this path-
way are associated with changes in pathway behavior,
and consequently, variations in response to treatment.
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ture for each of the samples, depicting molecular
expression and copy number, as well as interaction
activity and consistency visually in context. Whole net-
works and zoomed-in views of the network structure
for a few representative samples are shown in Figures 5
and 6.
This detailed graphical view is informative in a num-
ber of ways. It appears from Figure 5 that the resistant
lines are more frequently the target of copy number
alterations to molecules in this pathway. Notably
though, the same molecules are not altered in each line,
although their alteration may lead to the same end
result - disruption of pathway function. The pathway-
based analysis is able to capture this differentiation in
ways that a single-molecule based analysis could not. In
addition, a closer look at the network reveals the effect
these copy number alterations may have on molecular
expression, as well as other specific places in the path-
way where expression is differentiated.
Pathway Behavior and Patient Survival in Glioblastoma
Tumors
Publicly available normalized expression data [12] for
377 GBM tumor and 10 normal samples generated
using both the Affymetrix U133a platform and the Agi-
lent G4502A platform was downloaded from the TCGA
online database.
RMA-normalized data was loaded into the PathOlogist
as a text file. Up-Down Probability normalization was
then applied to the RMA data, and the results were
used to calculate activity and consistency scores for each
pathway in the database. A bi-dimensionally-clustered
heatmap of the scores for the 150 pathways with the
highest sample-wide variance in scores is shown in
Figure 2b.
Table 1 Ordered list of pathways with significant linear correlation between pathway metrics (either activity or
consistency) and GI50
Pathways Rho p value*
consistency: il2-mediated signaling events(NCI/Nature) 0.8049 2.18E-04
consistency: trk receptor signaling mediated by pi3k and plc-gamma(NCI/Nature) 0.791 4.91E-04
consistency: cadmium induces dna synthesis and proliferation in macrophages(Biocarta) 0.7511 3.71E-03
activity: toll-like receptor signaling pathway(Kegg) 0.7392 6.32E-03
activity: role of egf receptor transactivation by gpcrs in cardiac hypertrophy(Biocarta) 0.7042 2.60E-02
activity: agrin in postsynaptic differentiation(Biocarta) 0.694 3.80E-02
activity: downstream signaling in naïve cd8+ t cells(NCI/Nature) 0.6869 4.88E-02
*after Bonferroni correction.
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Figure 2 Bi-dimensionally clustered heatmap of pathway metrics, with separate rows for activity and consistency scores, for a) 28
cancer cell lines, and b) 368 GBM and 10 normal samples. In b), all 10 normal samples cluster together, as indicated by the colored bars to
the right.
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ples cluster naturally into a separate group, suggesting
that overall pathway-level behavior has been altered in
the tumor samples, and that our approach is able to
capture these alterations. Further analysis identified spe-
cific pathways that are most altered, including many
that have been previously implicated in GBM [13] such
as ERBB2 signaling (p < 8 × 10
-8), and TNF-alpha and
FAS signaling (p < 7 × 10
-8). Other pathway-based ana-
lyses (Paradigm [14], SPIA [15]) published 15 NCI/Nat-
ure pathways with the highest differential behavior
between tumor and normal samples. For direct compari-
son we compiled a list of the 15 top-ranked NCI/Nature
pathways from our analysis (Table 2), and find a num-
ber of similarities to previously reported pathways, parti-
cularly with regard to activity scores. Similarities include
pathways involved in Pi3k signaling (p < 9 × 10
-5)h i s -
tone deacytelase (HDAC) signaling (p < 9 × 10
-5), LPA-
receptor mediated events (p < 3 × 10
-4), p38 MAPK
signaling (p < 1 × 10
-4), and hif-1-alpha-mediated regu-
lation (p < 2 × 10
-4). This overlap suggests that our
method is able to find the important features in the
data, and identify pathways that are strongly correlated
with disease. Furthermore, when we consider the most
significantly altered pathways according to consistency
scores, many of the pathways we find have extensive
experimental evidence [16,17] for involvement in GBM
but have not yet been identified by other pathway-
centric tools. The RAC1, CDC42, FAS, and PDGFR sig-
naling pathways all appear in the top 15 pathways with
altered consistency (yet appear lower in our list accord-
ing to activity) and have been shown to play a large role
Figure 3 Scatterplots depicting relationship between GI50 and pathway metrics for two highly correlated pathways.
Figure 4 Heatmap of activity and consistency scores for the four pathways most highly correlated with sensitivity to treatment.
Samples were divided into four equal groups and labeled very sensitive, sensitive, resistant, or very resistant based on their response.
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use of activity and consistency metrics, our method is
able to capture both well-established and previously
unreported pathway-level alterations.
Within the set of tumor samples, we were also able to
identify pathways associated with survival. For each
pathway, samples were clustered into two groups based
on activity or consistency scores, and a logrank test was
performed comparing the Kaplan-Meier survival curve
of the two groups. A number of pathways separate sam-
ples into groups with significantly different survival
curves. Previous analysis with Paradigm identified path-
ways separating GBM samples into four subgroups, one
of which had a significantly increased survival. This
group was primarily characterized by upregulation of
E2F. Our pathway-based analysis finds that the ‘e2f tran-
scription factor network’ pathway is the only NCI/Nat-
ure pathway for which both activity and consistency are
significantly associated with survival. Additionally, we
find pathways involving p53, colorectal cancer, and
prostate cancer among the most significant.
Discussion
We believe that the integrated analysis made possible by
this tool will prove useful for pathway-based study of
biological information. Many tools currently exist that
infer networks from expression data. By contrast, the
PathOlogist predicts expression based on network
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Figure 5 Network structure of the Toll-like Receptor Signaling’ pathway, for two sensitive (a, b) and two resistant (c, d) cell lines.
Molecules with copy number alterations are outlined in yellow.
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Page 7 of 10structure, and then assesses whether actual gene expres-
sion systematically deviates from this prediction. Activity
and consistency scores provide a simple yet informative
summary of biologically complex behavior in a manner
immediately suitable for further statistical analyses. The
metrics generated by the PathOlogist can be used to
generate pathway signatures associated with clinical
data, or identify specific pathways implicated in disease
for further insight into disease pathology.
There are however, some limitations to this type of
analysis. The PathOlogist can only analyze established
pathways, and assumes the accuracy of the pathways in
the Pathway Interaction Database. Although the PID is
carefully curated to contain only high-quality, well-
documented pathways, there is still a certain amount of
ambiguity inherent in each pathway’s components,
structure, and boundaries. On the other hand, the
PathOlogist offers a possible check for pathway validity,
as it stands to reason that a pathway returning consis-
tently low consistency scores, even for normal samples,
could be assumed to lack biologic fidelity. Additionally,
since pathway scores are averages of the metrics asso-
ciated with each interaction within the pathway, small
subsets of interactions that have real association to a
clinical feature may be overshadowed by other non-cor-
related interactions, especially in large pathways.
Availability and Requirements
Project name: PathOlogist
Project home page: ftp://ftp1.nci.nih.gov/pub/pathologist/
Operating system: Windows
Programming language: MATLAB
CA SP8
CA SP8+
FADD
FADD+ IRAK1+
MYD8 8
MYD8 8 +
TLR5 TLR9
fm_721667 fm_721706
fm_721713 fm_721757
33:modification 34:modification 37:modification 44:modification 45:modification 46:modification 47:modification 71:modification
CA SP8
CA SP8+
FADD
FADD+ IRAK1+
MYD8 8
MYD8 8 +
TLR5 TLR9
fm_721667 fm_721706
fm_721713 fm_721757
33:modification 34:modification 37:modification 44:modification 45:modification 46:modification 47:modification 71:modification
Resistant Cell Line
Sensitive Cell Line
Figure 6 Portion of the ‘Toll-like Receptor Signaling’ pathway for two representative cell lines. Rectangles represent molecules, circles
represent interactions. Molecular expression is represented by shading of molecule nodes: white = lowest expression, bright turquoise = highest
expression. Molecules with copy number alterations are outlined in yellow. Interaction activity is represented by circle size: large circle = high
activity, small circle = low activity. Interaction consistency is represented by arrow color: bright blue: high consistency, dark green: low
consistency.
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Page 8 of 10Other Requirements: The full version of the tool
r e q u i r e sac o p yo fM A T L A Ba sw e l la sM A T L A B ’s
Bioinformatics and Statistics Toolboxes. The tool is
most stable when using MATLAB version 2009b and
later. The standalone version does not require MATLAB
but the RMA normalization and single-pathway graphics
features are not currently available. A step-by-step man-
ual for use of the PathOlogist is located at ftp://ftp1.nci.
nih.gov/pub/pathologist/The%20PathOlogist%20over-
view.doc (additional file 1).
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